3D model (JSmol)
|Molar mass||889.00 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Acetyl hexapeptide-3 or acetyl hexapeptide-8 (sources differ) is a synthetic anti-wrinkle cosmetics ingredient. It is a peptide which is a fragment of SNAP-25, a substrate of botulinum toxin (Botox). Acetyl hexapeptide-8 is marketed as Argireline by the Barcelona-based research laboratory Lipotec.
Overview and common uses
Chemically, when applied as a solution to specific areas of the face, acetyl hexapeptide-3 inhibits the reactions that cause muscles to move or contract – for example when forming facial expressions such as smiling or frowning.
In a 2012 double-blind, placebo-controlled trial investigating treatment of blepharospasm (abnormal contraction or twitch of the eyelid), botulinum toxin injections with subsequent acetyl hexapeptide-3 treatment were compared to botulinum toxin injections with placebo cream treatment. Of the 12 patients in the acetyl hexapeptide-3 group, four experienced an extension of symptom control by 3.3 to 7.1 months.
The 2012 study concluded there were no significant adverse effects. Patients receiving botulinum toxin injections exhibited longer times until return to baseline symptoms when supported with daily application of acetyl hexapeptide-8.
- Blanes-Mira, C; et al. (October 2002). "A synthetic hexapeptide (Argireline) with antiwrinkle activity". Int J Cosmet Sci. 24 (5): 303–10. doi:10.1046/j.1467-2494.2002.00153.x. PMID 18498523.
- Ruiz, MA; Clares, B; Morales, ME; Cazalla, S; Gallardo, V (2007). "Preparation and stability of cosmetic formulations with an anti-aging peptide". Journal of Cosmetic Science. 58 (2): 157–71. PMID 17520155.
- Lungu, MD, Codrin; Considine, RN, Elaine; Zahir, MS, Sana; Ponsati, PhD, Berta; Arrastia, MS, Silvia; Hallet, MD, Mark (November 12, 2012). "Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy". Eur J Neurol. 20 (3): 515–8. doi:10.1111/ene.12009. PMC 4747634. PMID 23146065.